Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted February 19, 2008
More Data on Avastin Benefit in Breast Cancer But Still PFS and not OS Improvement
Analysis of: Genentech’s Avastin Slows Spread Of Breast Cancer | www.pharmalot.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Avastin faces a substantial hurdle when it goes before the FDA for approval in first line breast cancer therapy.  There has been much debate over the progression free survival benefit (5.5 months) but no overall survival benefit for this agent.  The newly reported European data on Avastin...
Taral Patel Posted February 19, 2008
Avastin In Breast cancer
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
Author: Taral Patel, Oncologist Mid Ohio Oncology Hematology Inc.
New data with low and high dose of Avastin with Taxoter
Taral Patel Posted February 19, 2008
improve Overall survival in prostate cancer
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
Author: Taral Patel, Oncologist Mid Ohio Oncology Hematology Inc.
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
Posted February 18, 2008
Sutent's " Cardiac Worries" grow: Nexavar and Torisel to benefit
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: GLG Member Program Contributor
Yet another study, although small, report 15 5 incidence of cardiac abnormalities in patients receiving Pfizer's Sutent. The abnormalities persist and are serious in patients with previous history of cardiac disease. Sutent is an efficacious drug, but it has alternative options ( Nexavar and Torisel...
Posted February 18, 2008
SNPing to identify the genetic basis of prostate cancer
Analysis of: Prostate Cancer Genetics | www.nhs.uk
Author: GLG Member Program Contributor
Genome wide association studies compare the incidence of DNA sequence variants in large cohorts of patients and controls as a strategy to identify common genetic factors responsible for disease.  In three recent reports in Nature Genetics (Gudmundsson, Thomas and Eeles: 10 February 08) the Illumina...
Posted February 18, 2008
Sutent (Pfizer) causes heart failure?? Advantage Nexavar (Bayer/Onyx) and Torisel (Wyeth)
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: GLG Member Program Contributor
Sutent is associated with cardiac dysfunction!?
Posted February 18, 2008
FDA allowing info on non FDA approved uses? A bonus for Pharma but a nightmare for insurers.
Analysis of: F.D.A. Seeks to Broaden Range of Use for Drugs | www.nytimes.com
Author: GLG Member Program Contributor
As an oncologist we are aware of a drugs efficacy in conditions other than what it has been approved. Avastin in breast cancer; Nexavar and Erbitux in lung cancer, Taxotere in sarcomas. This list would be voluminous and would be a real benefit for patients BUT.......
Posted February 15, 2008
Avastin for recurrent breast cncer: improvement in time to progression may be enough for FDA approval!!!
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
Author: GLG Member Program Contributor
A recent trial showed that Genentech's Avastin when added to Docotaxel , increased time to progression in patients with recurrent breast cancer. This trial confirms results of a previous study and is reported to have better safety profile. Although survival data are still pending, the efficacy results...
Posted February 15, 2008
"Targeted" approach in both Ovarian and endometrial tumors? Very interesting and potentially effective!
Analysis of: Æterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers | www.pipelinereview.com
Author: GLG Member Program Contributor
Targeting gynecologic tumors with a "hormone" attached to an effective chemotherapeutic agent.
Posted February 14, 2008
Drop outs: a new key to unlocking cell survival and proliferation pathways in cancer
Analysis of: Gene discovery through functional genomics | www.ncbi.nlm.nih.gov
Author: GLG Member Program Contributor
In papers by Silva and Schlabach published in Science (1st Feb 08) RNA silencing was used to selectively remove genes, one at a time, from cancer cell lines in order to measure their influence on cell survival and proliferation. The beauty of the approach is that 1000s of genes can...
Previous Page : 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Next261 to 270 of 777

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T13:45:47.600